Monitoring Pharmaceutical Regulatory Trends in Each Country and Using Local Consultants
First written in FY2021. 1 of 3 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 3 of 16 companies on the "Worse" side.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In light of these risks, our group is working to rapidly monitor developments in each country's healthcare systems, pharmaceutical regulations and environmental regulations and will respond appropriately and in a timely manner.」
The scope of measures addressing regulatory risk was expanded to include monitoring and responding to developments in environmental regulations, in addition to healthcare systems and pharmaceutical regulations in each country. - FY2022RestatedAnnual report
「In light of these risks, our group is working to rapidly monitor developments in each country's healthcare systems and pharmaceutical regulations and will respond appropriately and in a timely manner.」
The company continues to pursue a policy of rapidly monitoring developments in each country's healthcare systems and pharmaceutical regulations and responding appropriately and in a timely manner. - FY2021First statedAnnual report
「In light of these risks, our group is working to rapidly monitor developments in pharmaceutical regulations in each country, including by utilizing local consultants as necessary.」
As countermeasures against the risk of changes in pharmaceutical regulations in each country, the company specifically cited for the first time the use of local consultants and the rapid monitoring of regulatory developments.